{"id":"maxigesic-iv","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Maxigesic IV is a fixed-dose combination of paracetamol (acetaminophen) and ibuprofen administered intravenously. Paracetamol acts primarily through central inhibition of prostaglandin synthesis and modulation of pain pathways, while ibuprofen is a non-selective NSAID that inhibits cyclooxygenase (COX-1 and COX-2) to reduce prostaglandin production peripherally and centrally. The combination provides synergistic analgesic and anti-inflammatory effects with potentially lower doses of each agent than used individually.","oneSentence":"Maxigesic IV combines paracetamol and ibuprofen to provide analgesia and anti-inflammation through dual inhibition of prostaglandin synthesis and central pain modulation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:20.157Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute postoperative pain"},{"name":"Moderate to severe pain requiring multimodal analgesia"}]},"trialDetails":[{"nctId":"NCT06015711","phase":"NA","title":"The Effect of Preoperative Maxigesic® on Intraoperative Remifentanil Requirement","status":"RECRUITING","sponsor":"Ajou University School of Medicine","startDate":"2023-08-30","conditions":"Opioid Use","enrollment":96},{"nctId":"NCT06174363","phase":"NA","title":"Analgesic Efficacy of Maxigesic in Breast Cancer Surgery","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2023-12-28","conditions":"Breast Cancer","enrollment":84},{"nctId":"NCT06479122","phase":"PHASE4","title":"Efficacy of Acetaminophen Alone Versus Combination of Acetaminophen/Ibuprofen After Cesarean Section","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2024-10-09","conditions":"Cesarean Section, Postoperative Pain","enrollment":84},{"nctId":"NCT06575049","phase":"","title":"Seroma and Hematoma Rates: MAXIGESIC IV vs. Ketorolac in Breast Cancer Surgery","status":"NOT_YET_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2025-05-01","conditions":"Breast Cancer, Post-Operative Hematoma, Seroma as Procedural Complication","enrollment":60},{"nctId":"NCT04005755","phase":"PHASE3","title":"Maxigesic® IV Phase 3 Exposure Study","status":"COMPLETED","sponsor":"AFT Pharmaceuticals, Ltd.","startDate":"2019-07-22","conditions":"Postoperative Pain","enrollment":232},{"nctId":"NCT02689063","phase":"PHASE3","title":"Maxigesic IV Phase 3 Bunionectomy Study","status":"COMPLETED","sponsor":"AFT Pharmaceuticals, Ltd.","startDate":"2016-10-26","conditions":"Post Operative Pain","enrollment":276}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Maxigesic"],"phase":"phase_3","status":"active","brandName":"Maxigesic IV","genericName":"Maxigesic IV","companyName":"AFT Pharmaceuticals, Ltd.","companyId":"aft-pharmaceuticals-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Maxigesic IV combines paracetamol and ibuprofen to provide analgesia and anti-inflammation through dual inhibition of prostaglandin synthesis and central pain modulation. Used for Acute postoperative pain, Moderate to severe pain requiring multimodal analgesia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}